Jubilant Pharmova Limited (JUBLPHARMA.NS)
INR 1085.05
(-0.42%)
INR 1085.05
(-0.42%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.8 Billion | 6.6 Billion | 8.37 Billion | 17.84 Billion | 15.42 Billion | 11.21 Billion |
| Net Income | 771 Million | 277.8 Million | 6.3 Billion | 12.12 Billion | 12.1 Billion | 9.03 Billion |
| Depreciation & Amortization | 3.81 Billion | 5.54 Billion | 3.81 Billion | 4.51 Billion | 4.61 Billion | 3.7 Billion |
| Deferred income taxes | - | -2.14 Billion | -1.4 Billion | -3.84 Billion | - | - |
| Stock-based compensation | 85 Million | 37 Million | 11.24 Million | 2.46 Million | - | - |
| Change in working capital | 2.53 Billion | 543.1 Million | -1.78 Billion | 2.49 Billion | -1.79 Billion | -3 Billion |
| Other non-cash items | 6.68 Billion | 2.35 Billion | 1.43 Billion | 2.54 Billion | 501.5 Million | 1.47 Billion |
| Investing Cash Flow | -6.6 Billion | -5.44 Billion | -3.8 Billion | -7.39 Billion | -3.27 Billion | -10.11 Billion |
| Investments in PPE | -8.97 Billion | -8.14 Billion | -5.99 Billion | -5.27 Billion | -5.74 Billion | -6.55 Billion |
| Acquisitions | 97 Million | 374.4 Million | -1.62 Billion | 131.94 Million | 310.65 Million | -101.69 Million |
| Investment purchases | -76 Million | -126.5 Million | -23.19 Million | -2.02 Billion | -36.39 Million | -40 Thousand |
| Sales/Maturities of investments | 57 Million | 8.9 Million | 2.14 Billion | -131.94 Million | 235.75 Million | 6.55 Billion |
| Other Investing Activities | 2.29 Billion | 2.44 Billion | 1.7 Billion | -90.94 Million | 1.96 Billion | -10.01 Billion |
| Financing Cash Flow | -1.88 Billion | -1.56 Billion | -325.99 Million | -17.09 Billion | -10.5 Billion | 6.57 Billion |
| Debt repayment | -204 Million | -27.72 Billion | -49.96 Million | -19.49 Billion | -16.1 Billion | -13.12 Billion |
| Dividends payments | -798 Million | -800.61 Million | -800.53 Million | -14.75 Million | -1.52 Billion | -545.86 Million |
| Common Stock Repurchased | -274 Million | -39.7 Million | - | -100.61 Million | 16.11 Billion | - |
| Common Stock Issuance | - | 27.76 Billion | - | -100.61 Million | 2.62 Million | 2.65 Billion |
| Other Financing Activities | -3.05 Billion | -766.22 Million | 524.5 Million | 2.62 Billion | -8.99 Billion | 17.58 Billion |
| Accounts receivables | 494 Million | 385.53 Million | -721.37 Million | -1.12 Billion | 2.19 Billion | -2.04 Billion |
| Accounts payables | 232 Million | 2.1 Billion | -427.14 Million | 2.28 Billion | -251.16 Million | 2.04 Billion |
| Inventory | 908 Million | -646.8 Million | -956.47 Million | 1.34 Billion | -3.74 Billion | 166.87 Million |
| Other working capital | 897 Million | -1.3 Billion | 322.11 Million | - | - | -3.17 Billion |
| Cash at beginning of period | 10.13 Billion | 9.83 Billion | 5.01 Billion | 12.3 Billion | 10.05 Billion | 2.44 Billion |
| Cash at end of period | 9.56 Billion | 10.13 Billion | 9.83 Billion | 5.01 Billion | 12.3 Billion | 10.05 Billion |
| Capital Expenditure | -8.97 Billion | -8.14 Billion | -5.99 Billion | -5.27 Billion | -5.74 Billion | -6.55 Billion |
| Effect of forex changes on cash | 116 Million | 705.3 Million | 572.88 Million | 122.59 Million | 598.52 Million | -58.83 Million |
| Net cash flow / Change in cash | -571.19 Million | 301 Million | 4.81 Billion | -7.28 Billion | 2.25 Billion | 7.61 Billion |
| Free Cash Flow | -1.17 Billion | -1.53 Billion | 2.37 Billion | 12.56 Billion | 9.68 Billion | 4.65 Billion |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 4.82 Billion | -586 Million | 771 Million | 668 Million | 625 Million | 64 Million |
| Depreciation & Amortization | - | - | 3.81 Billion | 946 Million | 966 Million | 897 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 85 Million | - | - | - |
| Change in working capital | - | - | 2.53 Billion | - | - | - |
| Other non-cash items | -4.82 Billion | 586 Million | 6.68 Billion | -668 Million | -625 Million | -64 Million |
| Investing Cash Flow | - | - | -6.6 Billion | - | - | - |
| Investments in PPE | - | - | -8.97 Billion | - | - | - |
| Acquisitions | - | - | 97 Million | - | - | - |
| Investment purchases | - | - | -76 Million | - | - | - |
| Sales/Maturities of investments | - | - | 57 Million | - | - | - |
| Other Investing Activities | - | - | 2.29 Billion | - | - | - |
| Financing Cash Flow | - | - | -1.88 Billion | - | - | - |
| Debt repayment | - | - | -204 Million | - | - | - |
| Dividends payments | - | - | -798 Million | - | - | - |
| Common Stock Repurchased | - | - | -274 Million | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -3.05 Billion | - | - | - |
| Accounts receivables | - | - | 494 Million | - | - | - |
| Accounts payables | - | - | 232 Million | - | - | - |
| Inventory | - | - | 908 Million | - | - | - |
| Other working capital | - | - | 897 Million | - | - | - |
| Cash at beginning of period | - | - | 10.13 Billion | 9.73 Billion | 7.8 Billion | 10.13 Billion |
| Cash at end of period | - | - | 9.56 Billion | 11.62 Billion | 9.73 Billion | 11.93 Billion |
| Capital Expenditure | - | - | -8.97 Billion | - | - | - |
| Effect of forex changes on cash | - | - | 116 Million | - | - | - |
| Net cash flow / Change in cash | - | - | -571.19 Million | 1.89 Billion | 1.93 Billion | 1.79 Billion |
| Free Cash Flow | - | - | -1.17 Billion | 1.89 Billion | 1.93 Billion | 1.79 Billion |
300220
CTRL
GR1T
OXBR
SUPREMEIND
VPLM